ERLOTINIB HYDROCHLORIDE
Application
Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line.
Biochem/physiol Actions
Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer.
General description
Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression.
| Colour | white to beige |
|---|---|
| InChI key | GTTBEUCJPZQMDZ-UHFFFAOYSA-N |
| InChI | 1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H |
| Manufacturer | SIGMA-ALDRICH |
| Storage Temp. | −20°C |
| Solubility | DMSO: 2 mg/mL, clear (warmed) |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
